XERS News and Press, Xeris Pharmaceuticals Inc. From 02/18/21

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xe...

Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolio's closet and haven't paid attention despite it hitting new 52-week highs. The company recently received European approval for their premixed RTU liqu...

Today, we take an in-depth look at specialty pharmaceutical concern Xeris Pharmaceuticals. The company has two approved products developed using their proprietary technology platform. A full investment analysis is as follows. For further details see: The Latest On Xeris ...

Artelo Biosciences (ARTL) +63%.China Liberal Education Holdings Limited (CLEU) +59%.Helius Medical Technologies (HSDT) +29%.Denison Mines Corp. (DNN) +26% on $25M bought deal offering.Xeris Pharmaceuticals (XERS) +25% as EC OK's its Ogluo for severe hypoglycaemia.Inovio Pharmaceutic...

Xeris Pharmaceuticals (XERS) jumps 13% premarket in reaction to the announcement that the European Commission ((EC)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in pediatric and adult patients with diabetes ages 2 years and above.The marketing a...

OGLUO™ Europe’s first and only ready-to-use liquid glucagon for rescue First availability expected in the fourth quarter Approval supported by data from pivotal Phase 3 study Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo (gl...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeri...

Are Analysts Right About These Penny Stocks? In this article, we’re going to explore a few things about penny stocks , what they are, and how to do research. We’ll also talk a bit about 5 of these stocks that analysts rate a buy right now. So let’s dive in. ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution a...